NASDAQ:GNOM Global X Genomics & Biotechnology ETF - GNOM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global X Genomics & Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. $11.92 -0.08 (-0.68%) (As of 03/30/2023 12:00 AM ET) Add Share Share Today's Range$11.82▼$12.1350-Day Range$11.73▼$14.1852-Week Range$10.48▼$16.75Volume37,421 shsAverage Volume78,420 shsMarket Capitalization$200.02 millionP/E RatioN/ADividend Yield0.00%Price TargetN/A ProfileChartFinancialsInstitutional OwnershipHeadlinesShort InterestSocial Media Global X Genomics & Biotechnology ETF MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.26% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.96 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Global X Genomics & Biotechnology ETF. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.26% of the outstanding shares of Global X Genomics & Biotechnology ETF have been sold short.Short Interest Ratio / Days to CoverGlobal X Genomics & Biotechnology ETF has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Global X Genomics & Biotechnology ETF has recently increased by 29.22%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGlobal X Genomics & Biotechnology ETF has a dividend yield of 0.00%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthGlobal X Genomics & Biotechnology ETF does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GNOM. Previous Next 1.9 News and Social Media Coverage News SentimentGlobal X Genomics & Biotechnology ETF has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Global X Genomics & Biotechnology ETF this week, compared to 0 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Global X Genomics & Biotechnology ETF insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.89% of the stock of Global X Genomics & Biotechnology ETF is held by insiders.Percentage Held by Institutions56.95% of the stock of Global X Genomics & Biotechnology ETF is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Global X Genomics & Biotechnology ETF is -5.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) StockComplete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.Read More Receive GNOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global X Genomics & Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address GNOM Stock News HeadlinesFebruary 16, 2023 | benzinga.comGlobal X Adaptive U.S. Risk Management ETF (ONOF): January 2023 ReportJanuary 18, 2023 | seekingalpha.comGNOM: Get Exposure To The Latest Genomics And Biotechnology CompaniesMarch 30, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!January 10, 2023 | markets.businessinsider.comComplete Genomics Launches Full Sequencing Platforms at Biotech Showcase™ 2023January 6, 2023 | benzinga.comGlobal X Adaptive U.S. Risk Management ETF (ONOF): November ReportOctober 12, 2022 | seekingalpha.com10x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish MomentumJuly 15, 2022 | benzinga.comWhat 5 Analyst Ratings Have To Say About 10x GenomicsJune 16, 2022 | benzinga.comNIH's National Human Genome Research Institute and NSTA Unveil New Genome: Unlocking Life's Code Educational Resources for EducatorsMarch 30, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!June 6, 2022 | markets.businessinsider.comUltima Genomics Collaborates with NVIDIA To Deliver $100 Genome Sequencing with AI and Accelerated ComputingDecember 29, 2021 | msn.comIs ARK's Stellar Run Over? 5 ETF Themes to Follow Cathie WoodDecember 22, 2021 | nasdaq.comGet Exposure to Global X Thematic ETFs in This One FundJuly 16, 2021 | nasdaq.comSnag Next-Generation Tech Exposure with This Genomics ETFJune 4, 2021 | msn.comETF Battles: ARKG vs. GNOM - Which Is The Better Genomics/Biotech Play?December 29, 2020 | msn.comTop-Performing Biotech ETFs Amid the COVID-19 CrisisDecember 24, 2020 | msn.com4 Best Sector ETFs of Q4December 23, 2020 | nasdaq.comGet On Board a Growing Biotech Industry With the GNOM ETFNovember 26, 2020 | barrons.comGlobal X Genomics & Biotechnology ETFNovember 25, 2020 | finance.yahoo.comETF Wrap: A very ETF Thanksgiving, and tax season tooOctober 18, 2020 | nasdaq.comGlobal X Genomics & Biotechnology ETF (GNOM)October 15, 2020 | msn.comWhy You Should Invest in Genomics ETFsJune 18, 2020 | www.nasdaq.comBiotechnology Is Hot, But It's Getting Scorching in This SegmentMay 26, 2020 | www.msn.com3 Genomics ETFs Worth Jumping ForMay 26, 2020 | finance.yahoo.comGenomics ETF (GNOM) Hits New 52-Week HighMarch 28, 2020 | markets.businessinsider.comThe single cell sequencing industry analysis projects the market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2029March 20, 2020 | www.marketwatch.comMicro Electro Mechanical Systems Market Emerging Opportunities, Growing Demand and Significant Trends by 2027March 19, 2020 | www.msn.com6 stocks that rose despite the coronavirus sell-offSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GNOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global X Genomics & Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:GNOM CUSIPN/A CIK1361103 Webwww.completegenomics.com Phone+1-650-9432800FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares16,780,000Free FloatN/AMarket Cap$201.70 million OptionableNot Optionable Beta1.02 Institutional OwnershipRockefeller Capital Management L.P.Bought 1,493 shares on 3/6/2023Ownership: 0.055%OLD Mission Capital LLCBought 2,899 shares on 3/6/2023Ownership: 0.017%Northwestern Mutual Wealth Management Co.Bought 154,330 shares on 2/21/2023Ownership: 39.881%Insight Advisors LLC PASold 5,570 shares on 2/21/2023Ownership: 0.152%Stelac Advisory Services LLCSold 758 shares on 2/16/2023Ownership: 0.071%View All Institutional Transactions GNOM Stock - Frequently Asked Questions How have GNOM shares performed in 2023? Global X Genomics & Biotechnology ETF's stock was trading at $12.65 at the beginning of 2023. Since then, GNOM shares have decreased by 5.0% and is now trading at $12.02. View the best growth stocks for 2023 here. Are investors shorting Global X Genomics & Biotechnology ETF? Global X Genomics & Biotechnology ETF saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 42,900 shares, an increase of 29.2% from the February 28th total of 33,200 shares. Based on an average daily trading volume, of 85,700 shares, the short-interest ratio is presently 0.5 days. View Global X Genomics & Biotechnology ETF's Short Interest. What ETFs hold Global X Genomics & Biotechnology ETF's stock? ETFs with the largest weight of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) stock in their portfolio include Global X Thematic Growth ETF (GXTG). What other stocks do shareholders of Global X Genomics & Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other Global X Genomics & Biotechnology ETF investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Sanofi (SNY), Intel (INTC), Pfizer (PFE), Quest Diagnostics (DGX), Micron Technology (MU), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB). What is Global X Genomics & Biotechnology ETF's stock symbol? Global X Genomics & Biotechnology ETF trades on the NASDAQ under the ticker symbol "GNOM." Who are Global X Genomics & Biotechnology ETF's major shareholders? Global X Genomics & Biotechnology ETF's stock is owned by a number of retail and institutional investors. Top institutional investors include Northwestern Mutual Wealth Management Co. (39.88%), Private Advisor Group LLC (6.47%), Mirae Asset Global Investments Co. Ltd. (3.01%), One Capital Management LLC (2.66%), McGuire Investment Group LLC (1.50%) and Portland Global Advisors LLC (1.29%). How do I buy shares of Global X Genomics & Biotechnology ETF? Shares of GNOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Global X Genomics & Biotechnology ETF's stock price today? One share of GNOM stock can currently be purchased for approximately $12.02. How much money does Global X Genomics & Biotechnology ETF make? Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) has a market capitalization of $201.70 million. How can I contact Global X Genomics & Biotechnology ETF? Global X Genomics & Biotechnology ETF's mailing address is 2071 Stierlin Ct, MOUNTAIN VIEW, CA 94043-4655, United States. The official website for the company is www.completegenomics.com. The company can be reached via phone at +1-650-9432800. This page (NASDAQ:GNOM) was last updated on 3/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.